The integration of AI in the pharmaceutical industry has yielded significant benefits, particularly in manufacturing and administrative operations, but its impact on drug discovery remains limited.
Diogo Rau, the Chief Information and Digital Officer at Eli Lilly, recently highlighted that AI's effectiveness has not yet materialized in drug discovery, despite substantial investments in technology partnerships and infrastructure. Major pharmaceutical companies like Roche, GSK, AstraZeneca, and Merck have also engaged in billion-dollar collaborations with AI firms, yet the anticipated advancements in drug development outcomes are still unproven. Analyst Trung Huynh from RBC notes that there is insufficient evidence to confirm that AI enhances clinical trial success rates.
While AI has not revolutionized drug discovery, its application in other areas has proven fruitful. For instance, Eli Lilly successfully implemented a digital twin for its manufacturing process of tirzepatide, leveraging machine learning to optimize production efficiency. This has resulted in faster manufacturing times and increased output.
There are some promising developments in drug discovery, such as Recursion Pharmaceuticals, which designed a cancer drug in just 18 months—significantly faster than the industry average. However, human trials still require extensive time. Overall, estimates suggest that AI could potentially save the U.S. pharmaceutical sector around $90 billion over the next five years, underlining its value in operational efficiency rather than groundbreaking research.